$EYE

National Vision Holdings, Inc. (EYE): Submission of Matters to a Vote of Security Holders

National Vision Holdings, Inc. (EYE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. eye-20260617 0001710155 false 0001710155 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________ FORM 8-K ________________________________________________________________

Original reporting
Published Jun 22, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$EYE
Neutral
high confidence
Mentioned
$EYE
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$EYENeutralLow
01

Why it matters

The disclosure confirms directors were elected, executive compensation received advisory approval, and Deloitte & Touche LLP was ratified as independent auditor for fiscal 2026; it does not introduce new financial metrics or corporate actions.

02

Market read

Primarily a compliance/governance update; not a fresh catalyst for valuation or risk.

03

What to watch

Traders may instead focus on upcoming earnings, guidance, or any separate 8-K items; this document contains only meeting outcomes.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (June 22, 2026) for June 17 vote results

Background

The company submitted SEC Form 8-K (Item 5.07) summarizing stockholder votes from its 2026 annual meeting held June 17, 2026.

Company-level read

Ticker impact

$EYENeutralHigh confidence
Context

National Vision Holdings filed an 8-K reporting June 17, 2026 annual meeting voting results for director elections and executive comp.

Expected impact

Limited near-term impact; any reaction is likely muted unless investors read governance implications into the vote totals.

Evidence & confidence

The filing is a standard Item 5.07 results report (director slate elected, advisory comp approved, Deloitte ratified) without new guidance, transactions, or enforcement actions.

Market effects

Minimal; governance vote results do not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

If governance is contested, unusually close vote counts could matter for activist/board-change expectations, but this filing alone provides no narrative or new dispute.

Key entities

  • National Vision Holdings, Inc.

    Nasdaq-listed company (EYE) reporting annual meeting voting results via SEC 8-K Item 5.07.

Related articles

$EYEMed

Itaconix Revenue Guidance Raised as Eagle Eye Beats on ARR

Itaconix (ITX) raised 2026 revenue guidance to at least $14.8m from $13.3m after H1 revenues rose 72% to $8.3m. It expects 2026 gross margin of 36% and said guidance supports breakeven and investment. Eagle Eye (EYE) reported FY26 results ahead of expectations, with ARR up 31% to £44.5m. Alumasc (ALU) suspended CEO Pamela Bingham and trimmed forecasts.

$EYEMedAI 9/10

National Vision (EYE) Becomes the Sole Eye Care Provider on Every US Army and Air Force Base

National Vision Holdings (EYE) reported Q1 2026 revenue of $543.9M, up 6.6% y/y, with adjusted EPS of $0.45 vs $0.43 expected. CFO Chris Laden cited higher average spend (+5.1%) but lower traffic (-1.2%). CEO Alex Wilkes attributed the EPS beat to cost controls. On April 1, EYE added 20 AAFES base optical locations, becoming sole provider on all US Army and Air Force bases (72 total).

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.